Clinical and morphological aspects of the management of crescentic anti-glomerular basement membrane antibody (anti-GBM) nephritis/Goodpasture's syndrome. 1985

R G Walker, and C Scheinkestel, and G J Becker, and J E Owen, and J P Dowling, and P Kincaid-Smith

Twenty-two patients with crescentic anti-GBM nephritis or Goodpasture's syndrome with renal impairment were reviewed. All patients were treated with a combination of plasma exchange and immunosuppression. Sixteen patients (73 per cent) showed improvement in renal function (greater than 30 per cent reduction in serum creatinine level) apparently in response to treatment, and nine patients (41 per cent) made long-term recoveries in renal function. The most important features carrying a bad prognosis were total anuria, and/or a very high percentage of glomeruli showing crescents (greater than 85 per cent) in the initial renal biopsy. Some patients with other so-called 'bad' prognostic features, including severely impaired renal function at presentation, oliguria and the need to institute dialysis had unexpected marked improvement in renal function and/or recovered renal function in the long term provided treatment with plasma exchange was begun promptly and maintained for a sufficient period to allow resolution of the disease process. Renal biopsies at the beginning and later proved to be an extremely valuable guide for the progress and outcome of the disease.

UI MeSH Term Description Entries
D007165 Immunosuppression Therapy Deliberate prevention or diminution of the host's immune response. It may be nonspecific as in the administration of immunosuppressive agents (drugs or radiation) or by lymphocyte depletion or may be specific as in desensitization or the simultaneous administration of antigen and immunosuppressive drugs. Antirejection Therapy,Immunosuppression,Immunosuppressive Therapy,Anti-Rejection Therapy,Therapy, Anti-Rejection,Therapy, Antirejection,Anti Rejection Therapy,Anti-Rejection Therapies,Antirejection Therapies,Immunosuppression Therapies,Immunosuppressions,Immunosuppressive Therapies,Therapies, Immunosuppression,Therapies, Immunosuppressive,Therapy, Immunosuppression,Therapy, Immunosuppressive
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010951 Plasma Exchange Removal of plasma and replacement with various fluids, e.g., fresh frozen plasma, plasma protein fractions (PPF), albumin preparations, dextran solutions, saline. Used in treatment of autoimmune diseases, immune complex diseases, diseases of excess plasma factors, and other conditions. Exchange, Plasma,Exchanges, Plasma,Plasma Exchanges
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011507 Proteinuria The presence of proteins in the urine, an indicator of KIDNEY DISEASES. Proteinurias
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D005260 Female Females
D005340 Fibrinogen Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products. Coagulation Factor I,Factor I,Blood Coagulation Factor I,gamma-Fibrinogen,Factor I, Coagulation,gamma Fibrinogen
D005921 Glomerulonephritis Inflammation of the renal glomeruli (KIDNEY GLOMERULUS) that can be classified by the type of glomerular injuries including antibody deposition, complement activation, cellular proliferation, and glomerulosclerosis. These structural and functional abnormalities usually lead to HEMATURIA; PROTEINURIA; HYPERTENSION; and RENAL INSUFFICIENCY. Bright Disease,Kidney Scarring,Glomerulonephritides,Scarring, Kidney

Related Publications

R G Walker, and C Scheinkestel, and G J Becker, and J E Owen, and J P Dowling, and P Kincaid-Smith
December 1983, Japanese journal of pharmacology,
R G Walker, and C Scheinkestel, and G J Becker, and J E Owen, and J P Dowling, and P Kincaid-Smith
January 1981, Nephron,
R G Walker, and C Scheinkestel, and G J Becker, and J E Owen, and J P Dowling, and P Kincaid-Smith
January 1996, Japanese journal of pharmacology,
R G Walker, and C Scheinkestel, and G J Becker, and J E Owen, and J P Dowling, and P Kincaid-Smith
January 2020, Academic pathology,
R G Walker, and C Scheinkestel, and G J Becker, and J E Owen, and J P Dowling, and P Kincaid-Smith
January 2017, European journal of case reports in internal medicine,
R G Walker, and C Scheinkestel, and G J Becker, and J E Owen, and J P Dowling, and P Kincaid-Smith
February 1980, Clinical nephrology,
R G Walker, and C Scheinkestel, and G J Becker, and J E Owen, and J P Dowling, and P Kincaid-Smith
November 2007, Seminars in immunopathology,
R G Walker, and C Scheinkestel, and G J Becker, and J E Owen, and J P Dowling, and P Kincaid-Smith
January 1992, American journal of industrial medicine,
R G Walker, and C Scheinkestel, and G J Becker, and J E Owen, and J P Dowling, and P Kincaid-Smith
January 2020, La Revue de medecine interne,
R G Walker, and C Scheinkestel, and G J Becker, and J E Owen, and J P Dowling, and P Kincaid-Smith
February 2018, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
Copied contents to your clipboard!